Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1552895
PUBLISHER: Grand View Research | PRODUCT CODE: 1552895
Cancer Biomarkers Market Size, Share & Trends Analysis Report By Type (Breast Cancer, Prostate Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, By Technology, By Region, And Segment Forecasts, 2024 - 2030
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Cancer Biomarkers Market Growth & Trends:
The global cancer biomarkers market size is expected to reach a value of USD 69.76 billion by 2030 and is anticipated to expand at a CAGR of 12.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing initiatives for development of drugs targeting novel cancer biomarkers coupled with the introduction of technologically advanced companion diagnostic kits is estimated to provide the market with high growth potential. Increasing awareness about personalized medicines amongst patients is further anticipated to boost adoption of cancer biomarkers.
In addition, presence of favorable government initiatives for the development of novel cancer diagnostic techniques is a key factor for market growth. For instance, the National Cancer Institute (NCI) provides funding to more than 8 research areas pertaining to cancer biomarker development. Cancer Research UK, Lung Cancer Research Foundation, and National Institutes of Health are some of the organizations providing funding for biomarker research.
People with high alcohol consumption, tobacco usage, unhealthy food habits, and sedentary lifestyle are reported to be 80% more at risk of developing cancer as compared to other individuals. Infections such as Human papillomavirus (HPV), Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori are also been studied to be related in cancer development.
Cancer Biomarkers Market Report Highlights:
- The breast cancer segment held a significant market share in terms of revenue in 2023 and it is also expected to be the witness the fastest CAGR over the forecast period.
- The others segment held a notable share in 2023 pertaining to the increased research on rare cancers, advancements in genomics and proteomics, the rising incidence of cancers such as pancreatic and ovarian, and the growing demand for personalized medicine.
- The genetic biomarkers segment dominated the market in terms of revenue share in 2023. Genetic biomarkers are crucial in the cancer biomarkers market due to several driving factors.
- The epigenetics segment is expected to be the fastest growing segment over the forecast period. One of the key drivers boosting the growth of the segment is the growing research for the development of novel biomarkers.
- The diagnostics segment dominated the market in terms of revenue share in 2023. Factors such as the growing development of cancer biomarkers based on oncology tests that are highly efficient and effective and growing government initiatives may drive the segment's growth.
- The personalized medicine segment is the fastest growing segment during the forecast period.
- The imaging technologies segment dominated the market share in 2023 due to its high-throughput nature, accuracy, and broad applicability in biomarker discovery and diagnosis.
- North America dominated the cancer biomarkers market with revenue share of 43.84% in 2023. This dominance is due to the presence of numerous market players dedicated to cancer biomarkers and substantial investments by the U.S. government in research and development efforts, which foster innovation.
- Asia Pacific cancer biomarkers market is anticipated to witness the fastest growth at a CAGR of 14.3% over the forecast period.
Product Code: GVR-1-68038-862-6
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Cancer Biomarkers Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Cancer Biomarkers Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- 3.4.1. Porter's Analysis
Chapter 4. Cancer Biomarkers Market: Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Cancer Biomarkers Market: Type Movement Analysis, 2023 & 2030 (USD Million)
- 4.3. Breast Cancer
- 4.3.1. Breast Cancer Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Prostate Cancer
- 4.4.1. Prostate Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Colorectal Cancer
- 4.5.1. Colorectal Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Cervical Cancer
- 4.6.1. Cervical Cancer Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.7. Liver Cancer
- 4.7.1. Liver Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.8. Lung Cancer
- 4.8.1. Lung Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.9. Others
- 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Cancer Biomarkers Market: Biomolecule Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Cancer Biomarkers Market: Biomolecule Movement Analysis, 2023 & 2030 (USD Million)
- 5.3. Genetic Biomarkers
- 5.3.1. Genetic Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Epigenetic Biomarkers
- 5.4.1. Epigenetic Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Metabolic Biomarkers
- 5.5.1. Metabolic Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Proteomic Biomarkers
- 5.6.1. Proteomic Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7. Others
- 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Cancer Biomarkers Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Cancer Biomarkers Market: Application Movement Analysis, 2023 & 2030 (USD Million)
- 6.3. Drug Discovery and Development
- 6.3.1. Drug Discovery and Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Diagnostics
- 6.4.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Personalized Medicine
- 6.5.1. Personalized Medicine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Others
- 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Cancer Biomarkers Market: Technology Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Cancer Biomarkers Market: Technology Movement Analysis, 2023 & 2030 (USD Million)
- 7.3. Imaging Technology
- 7.3.1. Imaging Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4. OMICS
- 7.4.1. OMICS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Cancer Biomarkers Market: Regional Estimates & Trend Analysis
- 8.1. Cancer Biomarkers Market Share, By Region, 2023 & 2030 (USD Million)
- 8.2. North America
- 8.2.1. North America Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.2. U.S.
- 8.2.2.1. U.S. Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.3. Canada
- 8.2.3.1. Canada Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.4. Mexico
- 8.2.4.1. Mexico Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3. Europe
- 8.3.1. Europe Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.2. UK
- 8.3.2.1. UK Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.3. Germany
- 8.3.3.1. Germany Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.4. France
- 8.3.4.1. France Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.5. Italy
- 8.3.5.1. Italy Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.6. Spain
- 8.3.6.1. Spain Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.7. Denmark
- 8.3.7.1. Denmark Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.8. Sweden
- 8.3.8.1. Sweden Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.9. Norway
- 8.3.9.1. Norway Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.2. Japan
- 8.4.2.1. Japan Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. China
- 8.4.3.1. China Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. India
- 8.4.4.1. India Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.5. Australia
- 8.4.5.1. Australia Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.6. Thailand
- 8.4.6.1. Thailand Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.7. South Korea
- 8.4.7.1. South Korea Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5. Latin America
- 8.5.1. Latin America Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. Brazil
- 8.5.2.1. Brazil Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Argentina
- 8.5.3.1. Argentina Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6. Middle East and Africa
- 8.6.1. Middle East and Africa Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. South Africa
- 8.6.2.1. South Africa Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. Saudi Arabia
- 8.6.3.1. Saudi Arabia Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. UAE
- 8.6.4.1. UAE Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Kuwait
- 8.6.5.1. Kuwait Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis by Key Market Participants
- 9.2. Company Categorization
- 9.3. Company Heat Map Analysis
- 9.4. Company Profiles
- 9.4.1. Abbott
- 9.4.1.1. Participant's Overview
- 9.4.1.2. Financial Performance
- 9.4.1.3. Product Benchmarking
- 9.4.1.4. Recent Developments/ Strategic Initiatives
- 9.4.2. QIAGEN
- 9.4.2.1. Participant's Overview
- 9.4.2.2. Financial Performance
- 9.4.2.3. Product Benchmarking
- 9.4.2.4. Recent Developments/ Strategic Initiatives
- 9.4.3. Thermo Fisher Scientific Inc
- 9.4.3.1. Participant's Overview
- 9.4.3.2. Financial Performance
- 9.4.3.3. Product Benchmarking
- 9.4.3.4. Recent Developments/ Strategic Initiatives
- 9.4.4. Affymetrix Inc
- 9.4.4.1. Participant's Overview
- 9.4.4.2. Financial Performance
- 9.4.4.3. Product Benchmarking
- 9.4.4.4. Recent Developments/ Strategic Initiatives
- 9.4.5. Illumina, Inc.
- 9.4.5.1. Participant's Overview
- 9.4.5.2. Financial Performance
- 9.4.5.3. Product Benchmarking
- 9.4.5.4. Recent Developments/ Strategic Initiatives
- 9.4.6. Agilent Technologies
- 9.4.6.1. Participant's Overview
- 9.4.6.2. Financial Performance
- 9.4.6.3. Product Benchmarking
- 9.4.6.4. Recent Developments/ Strategic Initiatives
- 9.4.7. F. Hoffmann-La Roche AG
- 9.4.7.1. Participant's Overview
- 9.4.7.2. Financial Performance
- 9.4.7.3. Product Benchmarking
- 9.4.7.4. Recent Developments/ Strategic Initiatives
- 9.4.8. Merck & Co. Inc
- 9.4.8.1. Participant's Overview
- 9.4.8.2. Financial Performance
- 9.4.8.3. Product Benchmarking
- 9.4.8.4. Recent Developments/ Strategic Initiatives
- 9.4.9. Hologic, Inc
- 9.4.9.1. Participant's Overview
- 9.4.9.2. Financial Performance
- 9.4.9.3. Product Benchmarking
- 9.4.9.4. Recent Developments/ Strategic Initiatives
- 9.4.10. Sino Biological Inc
- 9.4.10.1. Participant's Overview
- 9.4.10.2. Financial Performance
- 9.4.10.3. Product Benchmarking
- 9.4.10.4. Recent Developments/ Strategic Initiatives
- 9.4.1. Abbott
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.